nodes	percent_of_prediction	percent_of_DWPC	metapath
Ranolazine—Methocarbamol—CA1—esophageal cancer	0.0361	0.599	CrCbGaD
Ranolazine—Hypoaesthesia oral—Capecitabine—esophageal cancer	0.0261	0.0368	CcSEcCtD
Ranolazine—Chromaturia—Capecitabine—esophageal cancer	0.0191	0.0269	CcSEcCtD
Ranolazine—Carvedilol—HIF1A—esophageal cancer	0.0174	0.288	CrCbGaD
Ranolazine—Nephropathy toxic—Cisplatin—esophageal cancer	0.0161	0.0227	CcSEcCtD
Ranolazine—Serum creatinine increased—Cisplatin—esophageal cancer	0.015	0.0212	CcSEcCtD
Ranolazine—Altered state of consciousness—Capecitabine—esophageal cancer	0.0148	0.0208	CcSEcCtD
Ranolazine—Peripheral coldness—Capecitabine—esophageal cancer	0.0143	0.0202	CcSEcCtD
Ranolazine—Joint swelling—Capecitabine—esophageal cancer	0.0139	0.0196	CcSEcCtD
Ranolazine—Pulmonary fibrosis—Methotrexate—esophageal cancer	0.0115	0.0162	CcSEcCtD
Ranolazine—Serum creatinine increased—Capecitabine—esophageal cancer	0.0111	0.0156	CcSEcCtD
Ranolazine—Hearing impaired—Cisplatin—esophageal cancer	0.00972	0.0137	CcSEcCtD
Ranolazine—CYP2D6—Codeine and Morphine Metabolism—ABCC2—esophageal cancer	0.00825	0.0361	CbGpPWpGaD
Ranolazine—Renal failure acute—Cisplatin—esophageal cancer	0.00728	0.0102	CcSEcCtD
Ranolazine—Hearing impaired—Capecitabine—esophageal cancer	0.00717	0.0101	CcSEcCtD
Ranolazine—Amnesia—Cisplatin—esophageal cancer	0.00715	0.0101	CcSEcCtD
Ranolazine—Gait disturbance—Capecitabine—esophageal cancer	0.00699	0.00983	CcSEcCtD
Ranolazine—Coordination abnormal—Capecitabine—esophageal cancer	0.00695	0.00977	CcSEcCtD
Ranolazine—Depressed level of consciousness—Capecitabine—esophageal cancer	0.00659	0.00926	CcSEcCtD
Ranolazine—CYP2D6—Fatty Acid Omega Oxidation—ADH7—esophageal cancer	0.00652	0.0285	CbGpPWpGaD
Ranolazine—Blood creatinine increased—Cisplatin—esophageal cancer	0.00629	0.00885	CcSEcCtD
Ranolazine—Dehydration—Cisplatin—esophageal cancer	0.00625	0.00879	CcSEcCtD
Ranolazine—Orthostatic hypotension—Cisplatin—esophageal cancer	0.00613	0.00863	CcSEcCtD
Ranolazine—Breast disorder—Cisplatin—esophageal cancer	0.00607	0.00854	CcSEcCtD
Ranolazine—Cramp muscle—Cisplatin—esophageal cancer	0.00605	0.00851	CcSEcCtD
Ranolazine—CYP2D6—Fatty Acid Omega Oxidation—ADH1B—esophageal cancer	0.00572	0.025	CbGpPWpGaD
Ranolazine—Pancreatitis—Cisplatin—esophageal cancer	0.00569	0.00801	CcSEcCtD
Ranolazine—Abdominal discomfort—Cisplatin—esophageal cancer	0.00557	0.00783	CcSEcCtD
Ranolazine—Pancytopenia—Cisplatin—esophageal cancer	0.00551	0.00775	CcSEcCtD
Ranolazine—SCN5A—Cardiac Progenitor Differentiation—SOX2—esophageal cancer	0.00543	0.0237	CbGpPWpGaD
Ranolazine—CYP3A4—Codeine and Morphine Metabolism—ABCC2—esophageal cancer	0.00539	0.0236	CbGpPWpGaD
Ranolazine—Renal failure acute—Capecitabine—esophageal cancer	0.00536	0.00754	CcSEcCtD
Ranolazine—Hot flush—Capecitabine—esophageal cancer	0.00529	0.00744	CcSEcCtD
Ranolazine—Amnesia—Capecitabine—esophageal cancer	0.00527	0.00741	CcSEcCtD
Ranolazine—Menopausal symptoms—Capecitabine—esophageal cancer	0.00525	0.00738	CcSEcCtD
Ranolazine—CYP2D6—CYP2E1 reactions—CYP2A6—esophageal cancer	0.00511	0.0224	CbGpPWpGaD
Ranolazine—Renal failure—Cisplatin—esophageal cancer	0.00509	0.00716	CcSEcCtD
Ranolazine—Lethargy—Capecitabine—esophageal cancer	0.00505	0.00711	CcSEcCtD
Ranolazine—Pain in extremity—Capecitabine—esophageal cancer	0.00495	0.00696	CcSEcCtD
Ranolazine—Diplopia—Capecitabine—esophageal cancer	0.00495	0.00696	CcSEcCtD
Ranolazine—Depressed level of consciousness—Methotrexate—esophageal cancer	0.0049	0.0069	CcSEcCtD
Ranolazine—Bradycardia—Cisplatin—esophageal cancer	0.00473	0.00665	CcSEcCtD
Ranolazine—Urinary retention—Capecitabine—esophageal cancer	0.00471	0.00662	CcSEcCtD
Ranolazine—Blood creatinine increased—Capecitabine—esophageal cancer	0.00464	0.00652	CcSEcCtD
Ranolazine—Dehydration—Capecitabine—esophageal cancer	0.0046	0.00648	CcSEcCtD
Ranolazine—Urinary tract disorder—Cisplatin—esophageal cancer	0.00459	0.00645	CcSEcCtD
Ranolazine—Connective tissue disorder—Cisplatin—esophageal cancer	0.00457	0.00642	CcSEcCtD
Ranolazine—Urethral disorder—Cisplatin—esophageal cancer	0.00456	0.00641	CcSEcCtD
Ranolazine—Orthostatic hypotension—Capecitabine—esophageal cancer	0.00452	0.00636	CcSEcCtD
Ranolazine—Visual impairment—Cisplatin—esophageal cancer	0.00448	0.0063	CcSEcCtD
Ranolazine—Breast disorder—Capecitabine—esophageal cancer	0.00447	0.00629	CcSEcCtD
Ranolazine—CYP2D6—Codeine and Morphine Metabolism—ABCB1—esophageal cancer	0.00438	0.0191	CbGpPWpGaD
Ranolazine—Eye disorder—Cisplatin—esophageal cancer	0.00434	0.00611	CcSEcCtD
Ranolazine—Tinnitus—Cisplatin—esophageal cancer	0.00433	0.00609	CcSEcCtD
Ranolazine—Cardiac disorder—Cisplatin—esophageal cancer	0.00431	0.00607	CcSEcCtD
Ranolazine—CYP3A4—Fatty Acid Omega Oxidation—ADH7—esophageal cancer	0.00426	0.0186	CbGpPWpGaD
Ranolazine—Mediastinal disorder—Cisplatin—esophageal cancer	0.00419	0.00589	CcSEcCtD
Ranolazine—Arrhythmia—Cisplatin—esophageal cancer	0.00415	0.00584	CcSEcCtD
Ranolazine—Abdominal discomfort—Capecitabine—esophageal cancer	0.0041	0.00577	CcSEcCtD
Ranolazine—Pancytopenia—Capecitabine—esophageal cancer	0.00406	0.00572	CcSEcCtD
Ranolazine—Malnutrition—Cisplatin—esophageal cancer	0.00405	0.00569	CcSEcCtD
Ranolazine—CYP2D6—Fatty Acid Omega Oxidation—ALDH2—esophageal cancer	0.00403	0.0176	CbGpPWpGaD
Ranolazine—Dysuria—Capecitabine—esophageal cancer	0.004	0.00563	CcSEcCtD
Ranolazine—Renal failure acute—Methotrexate—esophageal cancer	0.00399	0.00562	CcSEcCtD
Ranolazine—Flatulence—Cisplatin—esophageal cancer	0.00399	0.00561	CcSEcCtD
Ranolazine—SCN5A—SIDS Susceptibility Pathways—ADCYAP1—esophageal cancer	0.00398	0.0174	CbGpPWpGaD
Ranolazine—Visual disturbance—Methotrexate—esophageal cancer	0.00389	0.00547	CcSEcCtD
Ranolazine—Muscle spasms—Cisplatin—esophageal cancer	0.00389	0.00547	CcSEcCtD
Ranolazine—Weight decreased—Capecitabine—esophageal cancer	0.00387	0.00545	CcSEcCtD
Ranolazine—Vision blurred—Cisplatin—esophageal cancer	0.00381	0.00536	CcSEcCtD
Ranolazine—Tremor—Cisplatin—esophageal cancer	0.00379	0.00533	CcSEcCtD
Ranolazine—CYP2D6—Fatty Acid Omega Oxidation—CYP2A6—esophageal cancer	0.00379	0.0166	CbGpPWpGaD
Ranolazine—Lethargy—Methotrexate—esophageal cancer	0.00376	0.00529	CcSEcCtD
Ranolazine—CYP3A4—Tryptophan metabolism—ALDH3A2—esophageal cancer	0.00375	0.0164	CbGpPWpGaD
Ranolazine—Renal failure—Capecitabine—esophageal cancer	0.00375	0.00528	CcSEcCtD
Ranolazine—CYP3A4—Fatty Acid Omega Oxidation—ADH1B—esophageal cancer	0.00374	0.0164	CbGpPWpGaD
Ranolazine—Carvedilol—PTGS1—esophageal cancer	0.00369	0.0612	CrCbGaD
Ranolazine—Haematuria—Capecitabine—esophageal cancer	0.00364	0.00512	CcSEcCtD
Ranolazine—Leukopenia—Cisplatin—esophageal cancer	0.00362	0.00509	CcSEcCtD
Ranolazine—Epistaxis—Capecitabine—esophageal cancer	0.0036	0.00506	CcSEcCtD
Ranolazine—Bradycardia—Capecitabine—esophageal cancer	0.00349	0.0049	CcSEcCtD
Ranolazine—CYP3A4—Irinotecan Pathway—ABCC2—esophageal cancer	0.00345	0.0151	CbGpPWpGaD
Ranolazine—Anxiety—Cisplatin—esophageal cancer	0.00343	0.00483	CcSEcCtD
Ranolazine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00342	0.00481	CcSEcCtD
Ranolazine—Hypoaesthesia—Capecitabine—esophageal cancer	0.00341	0.00479	CcSEcCtD
Ranolazine—Urinary tract disorder—Capecitabine—esophageal cancer	0.00338	0.00476	CcSEcCtD
Ranolazine—Oedema peripheral—Capecitabine—esophageal cancer	0.00337	0.00475	CcSEcCtD
Ranolazine—Connective tissue disorder—Capecitabine—esophageal cancer	0.00337	0.00473	CcSEcCtD
Ranolazine—Urethral disorder—Capecitabine—esophageal cancer	0.00336	0.00472	CcSEcCtD
Ranolazine—Breast disorder—Methotrexate—esophageal cancer	0.00333	0.00468	CcSEcCtD
Ranolazine—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—esophageal cancer	0.00331	0.0145	CbGpPWpGaD
Ranolazine—Visual impairment—Capecitabine—esophageal cancer	0.0033	0.00464	CcSEcCtD
Ranolazine—Nervous system disorder—Cisplatin—esophageal cancer	0.00324	0.00455	CcSEcCtD
Ranolazine—Thrombocytopenia—Cisplatin—esophageal cancer	0.00323	0.00455	CcSEcCtD
Ranolazine—Skin disorder—Cisplatin—esophageal cancer	0.00321	0.00451	CcSEcCtD
Ranolazine—Eye disorder—Capecitabine—esophageal cancer	0.0032	0.0045	CcSEcCtD
Ranolazine—Tinnitus—Capecitabine—esophageal cancer	0.00319	0.00449	CcSEcCtD
Ranolazine—Hyperhidrosis—Cisplatin—esophageal cancer	0.00319	0.00449	CcSEcCtD
Ranolazine—Cardiac disorder—Capecitabine—esophageal cancer	0.00318	0.00447	CcSEcCtD
Ranolazine—CYP2D6—Xenobiotics—CYP2A6—esophageal cancer	0.00317	0.0139	CbGpPWpGaD
Ranolazine—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—esophageal cancer	0.00316	0.0138	CbGpPWpGaD
Ranolazine—Eosinophilia—Methotrexate—esophageal cancer	0.00315	0.00444	CcSEcCtD
Ranolazine—Anorexia—Cisplatin—esophageal cancer	0.00315	0.00443	CcSEcCtD
Ranolazine—Pancreatitis—Methotrexate—esophageal cancer	0.00312	0.00439	CcSEcCtD
Ranolazine—Angiopathy—Capecitabine—esophageal cancer	0.00311	0.00437	CcSEcCtD
Ranolazine—Mediastinal disorder—Capecitabine—esophageal cancer	0.00309	0.00434	CcSEcCtD
Ranolazine—Hypotension—Cisplatin—esophageal cancer	0.00308	0.00434	CcSEcCtD
Ranolazine—Arrhythmia—Capecitabine—esophageal cancer	0.00306	0.0043	CcSEcCtD
Ranolazine—Abdominal discomfort—Methotrexate—esophageal cancer	0.00305	0.0043	CcSEcCtD
Ranolazine—CYP2D6—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.00305	0.0133	CbGpPWpGaD
Ranolazine—Pancytopenia—Methotrexate—esophageal cancer	0.00303	0.00426	CcSEcCtD
Ranolazine—Mental disorder—Capecitabine—esophageal cancer	0.003	0.00422	CcSEcCtD
Ranolazine—Malnutrition—Capecitabine—esophageal cancer	0.00298	0.00419	CcSEcCtD
Ranolazine—Dysuria—Methotrexate—esophageal cancer	0.00298	0.00419	CcSEcCtD
Ranolazine—Paraesthesia—Cisplatin—esophageal cancer	0.00296	0.00417	CcSEcCtD
Ranolazine—CYP3A4—Drug Induction of Bile Acid Pathway—ABCC2—esophageal cancer	0.00295	0.0129	CbGpPWpGaD
Ranolazine—Dyspnoea—Cisplatin—esophageal cancer	0.00294	0.00414	CcSEcCtD
Ranolazine—Flatulence—Capecitabine—esophageal cancer	0.00294	0.00413	CcSEcCtD
Ranolazine—Erectile dysfunction—Methotrexate—esophageal cancer	0.00293	0.00413	CcSEcCtD
Ranolazine—Decreased appetite—Cisplatin—esophageal cancer	0.00287	0.00404	CcSEcCtD
Ranolazine—Muscle spasms—Capecitabine—esophageal cancer	0.00287	0.00403	CcSEcCtD
Ranolazine—CYP3A4—Codeine and Morphine Metabolism—ABCB1—esophageal cancer	0.00286	0.0125	CbGpPWpGaD
Ranolazine—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00285	0.00401	CcSEcCtD
Ranolazine—Vision blurred—Capecitabine—esophageal cancer	0.00281	0.00395	CcSEcCtD
Ranolazine—Tremor—Capecitabine—esophageal cancer	0.00279	0.00393	CcSEcCtD
Ranolazine—Renal failure—Methotrexate—esophageal cancer	0.00279	0.00393	CcSEcCtD
Ranolazine—Feeling abnormal—Cisplatin—esophageal cancer	0.00272	0.00383	CcSEcCtD
Ranolazine—Haematuria—Methotrexate—esophageal cancer	0.00271	0.00381	CcSEcCtD
Ranolazine—Epistaxis—Methotrexate—esophageal cancer	0.00268	0.00377	CcSEcCtD
Ranolazine—Vertigo—Capecitabine—esophageal cancer	0.00268	0.00377	CcSEcCtD
Ranolazine—Syncope—Capecitabine—esophageal cancer	0.00267	0.00376	CcSEcCtD
Ranolazine—Leukopenia—Capecitabine—esophageal cancer	0.00267	0.00375	CcSEcCtD
Ranolazine—Palpitations—Capecitabine—esophageal cancer	0.00264	0.00371	CcSEcCtD
Ranolazine—CYP3A4—Fatty Acid Omega Oxidation—ALDH2—esophageal cancer	0.00263	0.0115	CbGpPWpGaD
Ranolazine—Loss of consciousness—Capecitabine—esophageal cancer	0.00262	0.00369	CcSEcCtD
Ranolazine—SCN9A—Axon guidance—PFN1—esophageal cancer	0.00262	0.0114	CbGpPWpGaD
Ranolazine—Cough—Capecitabine—esophageal cancer	0.0026	0.00366	CcSEcCtD
Ranolazine—SCN5A—SIDS Susceptibility Pathways—RUNX3—esophageal cancer	0.00257	0.0112	CbGpPWpGaD
Ranolazine—Anxiety—Capecitabine—esophageal cancer	0.00253	0.00356	CcSEcCtD
Ranolazine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00252	0.00355	CcSEcCtD
Ranolazine—Urinary tract disorder—Methotrexate—esophageal cancer	0.00252	0.00354	CcSEcCtD
Ranolazine—Urethral disorder—Methotrexate—esophageal cancer	0.0025	0.00352	CcSEcCtD
Ranolazine—Dry mouth—Capecitabine—esophageal cancer	0.00248	0.00349	CcSEcCtD
Ranolazine—CYP3A4—Fatty Acid Omega Oxidation—CYP2A6—esophageal cancer	0.00248	0.0108	CbGpPWpGaD
Ranolazine—Visual impairment—Methotrexate—esophageal cancer	0.00246	0.00346	CcSEcCtD
Ranolazine—CYP2D6—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.00246	0.0107	CbGpPWpGaD
Ranolazine—Confusional state—Capecitabine—esophageal cancer	0.00245	0.00345	CcSEcCtD
Ranolazine—SCN5A—Cardiac Progenitor Differentiation—KDR—esophageal cancer	0.00242	0.0106	CbGpPWpGaD
Ranolazine—Shock—Capecitabine—esophageal cancer	0.00239	0.00337	CcSEcCtD
Ranolazine—Nervous system disorder—Capecitabine—esophageal cancer	0.00239	0.00336	CcSEcCtD
Ranolazine—Eye disorder—Methotrexate—esophageal cancer	0.00238	0.00335	CcSEcCtD
Ranolazine—Thrombocytopenia—Capecitabine—esophageal cancer	0.00238	0.00335	CcSEcCtD
Ranolazine—Tinnitus—Methotrexate—esophageal cancer	0.00238	0.00334	CcSEcCtD
Ranolazine—SCN5A—SIDS Susceptibility Pathways—GAPDH—esophageal cancer	0.00237	0.0104	CbGpPWpGaD
Ranolazine—Asthenia—Cisplatin—esophageal cancer	0.00237	0.00333	CcSEcCtD
Ranolazine—Cardiac disorder—Methotrexate—esophageal cancer	0.00237	0.00333	CcSEcCtD
Ranolazine—Skin disorder—Capecitabine—esophageal cancer	0.00236	0.00332	CcSEcCtD
Ranolazine—Hyperhidrosis—Capecitabine—esophageal cancer	0.00235	0.00331	CcSEcCtD
Ranolazine—Anorexia—Capecitabine—esophageal cancer	0.00232	0.00326	CcSEcCtD
Ranolazine—Angiopathy—Methotrexate—esophageal cancer	0.00231	0.00325	CcSEcCtD
Ranolazine—Mediastinal disorder—Methotrexate—esophageal cancer	0.0023	0.00323	CcSEcCtD
Ranolazine—SCN5A—SIDS Susceptibility Pathways—SOX2—esophageal cancer	0.00229	0.01	CbGpPWpGaD
Ranolazine—SCN5A—Cardiac Progenitor Differentiation—NOTCH1—esophageal cancer	0.00228	0.00999	CbGpPWpGaD
Ranolazine—Hypotension—Capecitabine—esophageal cancer	0.00227	0.0032	CcSEcCtD
Ranolazine—Mental disorder—Methotrexate—esophageal cancer	0.00223	0.00314	CcSEcCtD
Ranolazine—Malnutrition—Methotrexate—esophageal cancer	0.00222	0.00312	CcSEcCtD
Ranolazine—Insomnia—Capecitabine—esophageal cancer	0.0022	0.0031	CcSEcCtD
Ranolazine—Paraesthesia—Capecitabine—esophageal cancer	0.00219	0.00307	CcSEcCtD
Ranolazine—Dyspnoea—Capecitabine—esophageal cancer	0.00217	0.00305	CcSEcCtD
Ranolazine—Dyspepsia—Capecitabine—esophageal cancer	0.00214	0.00301	CcSEcCtD
Ranolazine—SCN9A—Axon guidance—CFL1—esophageal cancer	0.00212	0.00927	CbGpPWpGaD
Ranolazine—Decreased appetite—Capecitabine—esophageal cancer	0.00212	0.00298	CcSEcCtD
Ranolazine—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.0021	0.00296	CcSEcCtD
Ranolazine—Vomiting—Cisplatin—esophageal cancer	0.0021	0.00295	CcSEcCtD
Ranolazine—Fatigue—Capecitabine—esophageal cancer	0.0021	0.00295	CcSEcCtD
Ranolazine—Vision blurred—Methotrexate—esophageal cancer	0.00209	0.00294	CcSEcCtD
Ranolazine—Rash—Cisplatin—esophageal cancer	0.00208	0.00293	CcSEcCtD
Ranolazine—Constipation—Capecitabine—esophageal cancer	0.00208	0.00293	CcSEcCtD
Ranolazine—Dermatitis—Cisplatin—esophageal cancer	0.00208	0.00293	CcSEcCtD
Ranolazine—CYP3A4—Xenobiotics—CYP2A6—esophageal cancer	0.00207	0.00906	CbGpPWpGaD
Ranolazine—Feeling abnormal—Capecitabine—esophageal cancer	0.00201	0.00282	CcSEcCtD
Ranolazine—Vertigo—Methotrexate—esophageal cancer	0.00199	0.00281	CcSEcCtD
Ranolazine—CYP3A4—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.00199	0.00871	CbGpPWpGaD
Ranolazine—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00199	0.0028	CcSEcCtD
Ranolazine—Leukopenia—Methotrexate—esophageal cancer	0.00199	0.00279	CcSEcCtD
Ranolazine—Nausea—Cisplatin—esophageal cancer	0.00196	0.00276	CcSEcCtD
Ranolazine—Cough—Methotrexate—esophageal cancer	0.00194	0.00272	CcSEcCtD
Ranolazine—Urticaria—Capecitabine—esophageal cancer	0.00193	0.00272	CcSEcCtD
Ranolazine—Abdominal pain—Capecitabine—esophageal cancer	0.00192	0.00271	CcSEcCtD
Ranolazine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.0019	0.00832	CbGpPWpGaD
Ranolazine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.0019	0.00832	CbGpPWpGaD
Ranolazine—CYP2D6—Melatonin metabolism and effects—CYP1B1—esophageal cancer	0.0019	0.0083	CbGpPWpGaD
Ranolazine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00188	0.00264	CcSEcCtD
Ranolazine—SCN9A—Developmental Biology—PFN1—esophageal cancer	0.00187	0.00816	CbGpPWpGaD
Ranolazine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.00185	0.00808	CbGpPWpGaD
Ranolazine—CYP2D6—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.00184	0.00803	CbGpPWpGaD
Ranolazine—Confusional state—Methotrexate—esophageal cancer	0.00183	0.00257	CcSEcCtD
Ranolazine—CYP2D6—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.00182	0.00797	CbGpPWpGaD
Ranolazine—CYP3A4—Estrogen metabolism—CYP1B1—esophageal cancer	0.00182	0.00795	CbGpPWpGaD
Ranolazine—SCN9A—Axon guidance—ACTB—esophageal cancer	0.0018	0.00788	CbGpPWpGaD
Ranolazine—Carvedilol—ABCB1—esophageal cancer	0.0018	0.0297	CrCbGaD
Ranolazine—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.00178	0.00778	CbGpPWpGaD
Ranolazine—SCN5A—SIDS Susceptibility Pathways—SST—esophageal cancer	0.00178	0.00778	CbGpPWpGaD
Ranolazine—Nervous system disorder—Methotrexate—esophageal cancer	0.00178	0.0025	CcSEcCtD
Ranolazine—Thrombocytopenia—Methotrexate—esophageal cancer	0.00177	0.00249	CcSEcCtD
Ranolazine—Skin disorder—Methotrexate—esophageal cancer	0.00176	0.00248	CcSEcCtD
Ranolazine—Hyperhidrosis—Methotrexate—esophageal cancer	0.00175	0.00246	CcSEcCtD
Ranolazine—Asthenia—Capecitabine—esophageal cancer	0.00175	0.00246	CcSEcCtD
Ranolazine—Anorexia—Methotrexate—esophageal cancer	0.00173	0.00243	CcSEcCtD
Ranolazine—Pruritus—Capecitabine—esophageal cancer	0.00172	0.00242	CcSEcCtD
Ranolazine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.0017	0.00741	CbGpPWpGaD
Ranolazine—Hypotension—Methotrexate—esophageal cancer	0.00169	0.00238	CcSEcCtD
Ranolazine—Insomnia—Methotrexate—esophageal cancer	0.00164	0.0023	CcSEcCtD
Ranolazine—SCN5A—Axon guidance—PFN1—esophageal cancer	0.00163	0.00713	CbGpPWpGaD
Ranolazine—Paraesthesia—Methotrexate—esophageal cancer	0.00163	0.00229	CcSEcCtD
Ranolazine—Dyspnoea—Methotrexate—esophageal cancer	0.00162	0.00227	CcSEcCtD
Ranolazine—Somnolence—Methotrexate—esophageal cancer	0.00161	0.00227	CcSEcCtD
Ranolazine—CYP2D6—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.00161	0.00704	CbGpPWpGaD
Ranolazine—Dizziness—Capecitabine—esophageal cancer	0.00161	0.00226	CcSEcCtD
Ranolazine—CYP3A4—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.00161	0.00702	CbGpPWpGaD
Ranolazine—Dyspepsia—Methotrexate—esophageal cancer	0.00159	0.00224	CcSEcCtD
Ranolazine—Decreased appetite—Methotrexate—esophageal cancer	0.00157	0.00222	CcSEcCtD
Ranolazine—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—esophageal cancer	0.00157	0.00685	CbGpPWpGaD
Ranolazine—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00156	0.0022	CcSEcCtD
Ranolazine—Fatigue—Methotrexate—esophageal cancer	0.00156	0.0022	CcSEcCtD
Ranolazine—Vomiting—Capecitabine—esophageal cancer	0.00155	0.00218	CcSEcCtD
Ranolazine—Rash—Capecitabine—esophageal cancer	0.00153	0.00216	CcSEcCtD
Ranolazine—Dermatitis—Capecitabine—esophageal cancer	0.00153	0.00216	CcSEcCtD
Ranolazine—Headache—Capecitabine—esophageal cancer	0.00152	0.00214	CcSEcCtD
Ranolazine—SCN9A—Developmental Biology—CFL1—esophageal cancer	0.00151	0.00661	CbGpPWpGaD
Ranolazine—CYP2D6—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.0015	0.00655	CbGpPWpGaD
Ranolazine—Feeling abnormal—Methotrexate—esophageal cancer	0.00149	0.0021	CcSEcCtD
Ranolazine—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00148	0.00208	CcSEcCtD
Ranolazine—SCN9A—Developmental Biology—SOX2—esophageal cancer	0.00146	0.00639	CbGpPWpGaD
Ranolazine—Nausea—Capecitabine—esophageal cancer	0.00145	0.00203	CcSEcCtD
Ranolazine—Urticaria—Methotrexate—esophageal cancer	0.00144	0.00202	CcSEcCtD
Ranolazine—Abdominal pain—Methotrexate—esophageal cancer	0.00143	0.00201	CcSEcCtD
Ranolazine—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.00142	0.00622	CbGpPWpGaD
Ranolazine—Propranolol—ABCB1—esophageal cancer	0.00137	0.0226	CrCbGaD
Ranolazine—SCN5A—Axon guidance—CFL1—esophageal cancer	0.00132	0.00577	CbGpPWpGaD
Ranolazine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.00132	0.00576	CbGpPWpGaD
Ranolazine—Asthenia—Methotrexate—esophageal cancer	0.0013	0.00183	CcSEcCtD
Ranolazine—CYP2D6—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.0013	0.00568	CbGpPWpGaD
Ranolazine—SCN9A—Developmental Biology—ACTB—esophageal cancer	0.00129	0.00562	CbGpPWpGaD
Ranolazine—Pruritus—Methotrexate—esophageal cancer	0.00128	0.0018	CcSEcCtD
Ranolazine—SCN9A—Developmental Biology—CTNNA1—esophageal cancer	0.00126	0.00552	CbGpPWpGaD
Ranolazine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.00121	0.00528	CbGpPWpGaD
Ranolazine—SCN9A—Axon guidance—ABL1—esophageal cancer	0.00121	0.00528	CbGpPWpGaD
Ranolazine—CYP3A4—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.0012	0.00525	CbGpPWpGaD
Ranolazine—SCN9A—L1CAM interactions—EGFR—esophageal cancer	0.0012	0.00525	CbGpPWpGaD
Ranolazine—Dizziness—Methotrexate—esophageal cancer	0.0012	0.00168	CcSEcCtD
Ranolazine—CYP3A4—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.00119	0.00521	CbGpPWpGaD
Ranolazine—SCN5A—Developmental Biology—PFN1—esophageal cancer	0.00116	0.00509	CbGpPWpGaD
Ranolazine—Vomiting—Methotrexate—esophageal cancer	0.00115	0.00162	CcSEcCtD
Ranolazine—Rash—Methotrexate—esophageal cancer	0.00114	0.00161	CcSEcCtD
Ranolazine—Dermatitis—Methotrexate—esophageal cancer	0.00114	0.00161	CcSEcCtD
Ranolazine—Headache—Methotrexate—esophageal cancer	0.00113	0.0016	CcSEcCtD
Ranolazine—CYP2D6—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.00113	0.00496	CbGpPWpGaD
Ranolazine—CYP3A4—Tryptophan metabolism—ALDH2—esophageal cancer	0.00113	0.00495	CbGpPWpGaD
Ranolazine—SCN5A—Axon guidance—ACTB—esophageal cancer	0.00112	0.00491	CbGpPWpGaD
Ranolazine—Nausea—Methotrexate—esophageal cancer	0.00108	0.00151	CcSEcCtD
Ranolazine—SCN5A—SIDS Susceptibility Pathways—HIF1A—esophageal cancer	0.00107	0.00467	CbGpPWpGaD
Ranolazine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.00107	0.00467	CbGpPWpGaD
Ranolazine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.00106	0.00464	CbGpPWpGaD
Ranolazine—CYP3A4—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.00105	0.0046	CbGpPWpGaD
Ranolazine—CYP2D6—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.00105	0.00458	CbGpPWpGaD
Ranolazine—CYP2D6—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.00101	0.00442	CbGpPWpGaD
Ranolazine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000997	0.00436	CbGpPWpGaD
Ranolazine—CYP2D6—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000984	0.0043	CbGpPWpGaD
Ranolazine—CYP3A4—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.000979	0.00428	CbGpPWpGaD
Ranolazine—CYP2D6—Biological oxidations—ADH7—esophageal cancer	0.000976	0.00427	CbGpPWpGaD
Ranolazine—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.000944	0.00413	CbGpPWpGaD
Ranolazine—SCN5A—Developmental Biology—CFL1—esophageal cancer	0.000942	0.00412	CbGpPWpGaD
Ranolazine—SCN9A—Axon guidance—KDR—esophageal cancer	0.000914	0.004	CbGpPWpGaD
Ranolazine—SCN5A—Developmental Biology—SOX2—esophageal cancer	0.00091	0.00398	CbGpPWpGaD
Ranolazine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.0009	0.00393	CbGpPWpGaD
Ranolazine—SCN9A—Axon guidance—MET—esophageal cancer	0.000895	0.00391	CbGpPWpGaD
Ranolazine—SCN5A—SIDS Susceptibility Pathways—CREBBP—esophageal cancer	0.000873	0.00382	CbGpPWpGaD
Ranolazine—SCN9A—Developmental Biology—ABL1—esophageal cancer	0.000861	0.00376	CbGpPWpGaD
Ranolazine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.00086	0.00376	CbGpPWpGaD
Ranolazine—CYP2D6—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.00086	0.00376	CbGpPWpGaD
Ranolazine—CYP3A4—Tryptophan metabolism—CYP1B1—esophageal cancer	0.000858	0.00375	CbGpPWpGaD
Ranolazine—CYP2D6—Biological oxidations—ADH1B—esophageal cancer	0.000855	0.00374	CbGpPWpGaD
Ranolazine—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.000849	0.00371	CbGpPWpGaD
Ranolazine—SCN9A—Developmental Biology—SMAD4—esophageal cancer	0.000834	0.00365	CbGpPWpGaD
Ranolazine—CYP2D6—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000808	0.00354	CbGpPWpGaD
Ranolazine—CYP3A4—Tryptophan metabolism—CYP19A1—esophageal cancer	0.000806	0.00353	CbGpPWpGaD
Ranolazine—SCN5A—Developmental Biology—ACTB—esophageal cancer	0.000801	0.0035	CbGpPWpGaD
Ranolazine—CYP2D6—Biological oxidations—CYP26A1—esophageal cancer	0.000795	0.00348	CbGpPWpGaD
Ranolazine—SCN5A—Developmental Biology—CTNNA1—esophageal cancer	0.000787	0.00344	CbGpPWpGaD
Ranolazine—CYP2D6—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000784	0.00343	CbGpPWpGaD
Ranolazine—SCN5A—Axon guidance—ABL1—esophageal cancer	0.000751	0.00329	CbGpPWpGaD
Ranolazine—SCN5A—L1CAM interactions—EGFR—esophageal cancer	0.000747	0.00327	CbGpPWpGaD
Ranolazine—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000742	0.00324	CbGpPWpGaD
Ranolazine—CYP2D6—Biological oxidations—GSTO1—esophageal cancer	0.000739	0.00323	CbGpPWpGaD
Ranolazine—CYP2D6—Metapathway biotransformation—GSTO1—esophageal cancer	0.000729	0.00319	CbGpPWpGaD
Ranolazine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000697	0.00305	CbGpPWpGaD
Ranolazine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000693	0.00303	CbGpPWpGaD
Ranolazine—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000684	0.00299	CbGpPWpGaD
Ranolazine—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000661	0.00289	CbGpPWpGaD
Ranolazine—SCN9A—Axon guidance—ERBB2—esophageal cancer	0.000654	0.00286	CbGpPWpGaD
Ranolazine—SCN9A—Developmental Biology—KDR—esophageal cancer	0.000652	0.00285	CbGpPWpGaD
Ranolazine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000652	0.00285	CbGpPWpGaD
Ranolazine—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000643	0.00281	CbGpPWpGaD
Ranolazine—SCN9A—Developmental Biology—MET—esophageal cancer	0.000638	0.00279	CbGpPWpGaD
Ranolazine—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.000638	0.00279	CbGpPWpGaD
Ranolazine—SCN9A—Developmental Biology—NOTCH1—esophageal cancer	0.000615	0.00269	CbGpPWpGaD
Ranolazine—CYP2D6—Biological oxidations—ALDH2—esophageal cancer	0.000603	0.00264	CbGpPWpGaD
Ranolazine—SCN5A—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.000594	0.0026	CbGpPWpGaD
Ranolazine—CYP2D6—Biological oxidations—GSTT1—esophageal cancer	0.000573	0.00251	CbGpPWpGaD
Ranolazine—SCN5A—Axon guidance—KDR—esophageal cancer	0.000569	0.00249	CbGpPWpGaD
Ranolazine—CYP2D6—Biological oxidations—CYP2A6—esophageal cancer	0.000567	0.00248	CbGpPWpGaD
Ranolazine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000562	0.00246	CbGpPWpGaD
Ranolazine—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000559	0.00245	CbGpPWpGaD
Ranolazine—SCN5A—Axon guidance—MET—esophageal cancer	0.000557	0.00244	CbGpPWpGaD
Ranolazine—SCN9A—Developmental Biology—CREBBP—esophageal cancer	0.000557	0.00244	CbGpPWpGaD
Ranolazine—CYP2D6—Biological oxidations—PTGS1—esophageal cancer	0.000537	0.00235	CbGpPWpGaD
Ranolazine—SCN5A—Developmental Biology—ABL1—esophageal cancer	0.000536	0.00235	CbGpPWpGaD
Ranolazine—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000529	0.00231	CbGpPWpGaD
Ranolazine—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.00052	0.00227	CbGpPWpGaD
Ranolazine—SCN5A—Developmental Biology—SMAD4—esophageal cancer	0.000519	0.00227	CbGpPWpGaD
Ranolazine—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000513	0.00224	CbGpPWpGaD
Ranolazine—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.000483	0.00211	CbGpPWpGaD
Ranolazine—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.000477	0.00208	CbGpPWpGaD
Ranolazine—SCN9A—Developmental Biology—ERBB2—esophageal cancer	0.000467	0.00204	CbGpPWpGaD
Ranolazine—CYP2D6—Biological oxidations—CYP1B1—esophageal cancer	0.000457	0.002	CbGpPWpGaD
Ranolazine—SCN9A—Axon guidance—EGFR—esophageal cancer	0.000453	0.00198	CbGpPWpGaD
Ranolazine—CYP2D6—Metapathway biotransformation—CYP1B1—esophageal cancer	0.00045	0.00197	CbGpPWpGaD
Ranolazine—CYP2D6—Biological oxidations—CYP19A1—esophageal cancer	0.000429	0.00188	CbGpPWpGaD
Ranolazine—CYP2D6—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000424	0.00185	CbGpPWpGaD
Ranolazine—SCN5A—Axon guidance—ERBB2—esophageal cancer	0.000407	0.00178	CbGpPWpGaD
Ranolazine—SCN5A—Developmental Biology—KDR—esophageal cancer	0.000406	0.00178	CbGpPWpGaD
Ranolazine—SCN5A—Developmental Biology—MET—esophageal cancer	0.000398	0.00174	CbGpPWpGaD
Ranolazine—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.000394	0.00172	CbGpPWpGaD
Ranolazine—SCN5A—Developmental Biology—NOTCH1—esophageal cancer	0.000383	0.00167	CbGpPWpGaD
Ranolazine—SCN9A—Developmental Biology—EP300—esophageal cancer	0.000379	0.00166	CbGpPWpGaD
Ranolazine—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.000375	0.00164	CbGpPWpGaD
Ranolazine—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.00037	0.00162	CbGpPWpGaD
Ranolazine—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000351	0.00154	CbGpPWpGaD
Ranolazine—SCN5A—Developmental Biology—CREBBP—esophageal cancer	0.000347	0.00152	CbGpPWpGaD
Ranolazine—SCN9A—Developmental Biology—EGFR—esophageal cancer	0.000323	0.00141	CbGpPWpGaD
Ranolazine—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.000299	0.00131	CbGpPWpGaD
Ranolazine—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000295	0.00129	CbGpPWpGaD
Ranolazine—SCN5A—Developmental Biology—ERBB2—esophageal cancer	0.000291	0.00127	CbGpPWpGaD
Ranolazine—SCN5A—Axon guidance—EGFR—esophageal cancer	0.000282	0.00123	CbGpPWpGaD
Ranolazine—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000281	0.00123	CbGpPWpGaD
Ranolazine—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000277	0.00121	CbGpPWpGaD
Ranolazine—SCN5A—Developmental Biology—EP300—esophageal cancer	0.000236	0.00103	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—SLC52A3—esophageal cancer	0.000231	0.00101	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—BLVRB—esophageal cancer	0.000231	0.00101	CbGpPWpGaD
Ranolazine—SCN5A—Developmental Biology—EGFR—esophageal cancer	0.000201	0.000881	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—CA1—esophageal cancer	0.000196	0.000858	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—SLC10A2—esophageal cancer	0.000196	0.000858	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—CA2—esophageal cancer	0.000179	0.000785	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—PLCE1—esophageal cancer	0.000167	0.00073	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—ADH7—esophageal cancer	0.000167	0.00073	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—BLVRB—esophageal cancer	0.000151	0.00066	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—SLC52A3—esophageal cancer	0.000151	0.00066	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—ADH1B—esophageal cancer	0.000146	0.00064	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—TYMP—esophageal cancer	0.00014	0.000611	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—CYP26A1—esophageal cancer	0.000136	0.000595	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—ALOX15—esophageal cancer	0.000133	0.00058	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—CA1—esophageal cancer	0.000128	0.000561	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—SLC10A2—esophageal cancer	0.000128	0.000561	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—GSTO1—esophageal cancer	0.000126	0.000553	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—TPI1—esophageal cancer	0.000126	0.000553	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—ALDOB—esophageal cancer	0.000121	0.00053	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—CA2—esophageal cancer	0.000117	0.000513	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—GAPDH—esophageal cancer	0.000117	0.00051	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—CRABP1—esophageal cancer	0.000116	0.000506	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—GNG7—esophageal cancer	0.00011	0.000481	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—PLCE1—esophageal cancer	0.000109	0.000477	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—ADH7—esophageal cancer	0.000109	0.000477	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—ALDH2—esophageal cancer	0.000103	0.000451	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—GSTT1—esophageal cancer	9.8e-05	0.000429	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—CYP2A6—esophageal cancer	9.69e-05	0.000424	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—ADH1B—esophageal cancer	9.56e-05	0.000418	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—ENO1—esophageal cancer	9.19e-05	0.000402	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—PTGS1—esophageal cancer	9.19e-05	0.000402	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—TYMP—esophageal cancer	9.14e-05	0.0004	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—PSME2—esophageal cancer	9.05e-05	0.000396	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—PSME1—esophageal cancer	9.05e-05	0.000396	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—CYP26A1—esophageal cancer	8.89e-05	0.000389	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—ALOX15—esophageal cancer	8.67e-05	0.000379	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—TPI1—esophageal cancer	8.27e-05	0.000362	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—GSTO1—esophageal cancer	8.27e-05	0.000362	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—ALDOB—esophageal cancer	7.93e-05	0.000347	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—CYP1B1—esophageal cancer	7.81e-05	0.000342	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—GAPDH—esophageal cancer	7.63e-05	0.000334	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—CRABP1—esophageal cancer	7.56e-05	0.000331	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—CYP19A1—esophageal cancer	7.34e-05	0.000321	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—GNG7—esophageal cancer	7.19e-05	0.000315	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—ALDH2—esophageal cancer	6.74e-05	0.000295	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—HMOX1—esophageal cancer	6.7e-05	0.000293	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—ABCB1—esophageal cancer	6.43e-05	0.000281	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—GSTT1—esophageal cancer	6.41e-05	0.00028	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—CYP2A6—esophageal cancer	6.34e-05	0.000277	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—ENO1—esophageal cancer	6.01e-05	0.000263	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—PTGS1—esophageal cancer	6.01e-05	0.000263	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—PSME2—esophageal cancer	5.92e-05	0.000259	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—PSME1—esophageal cancer	5.92e-05	0.000259	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—CYP1B1—esophageal cancer	5.11e-05	0.000223	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—CYP19A1—esophageal cancer	4.8e-05	0.00021	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—HMOX1—esophageal cancer	4.38e-05	0.000192	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—CREBBP—esophageal cancer	4.3e-05	0.000188	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—ABCB1—esophageal cancer	4.21e-05	0.000184	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—NOS3—esophageal cancer	3.85e-05	0.000168	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—PTGS2—esophageal cancer	3.52e-05	0.000154	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—EP300—esophageal cancer	2.93e-05	0.000128	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—CREBBP—esophageal cancer	2.81e-05	0.000123	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—NOS3—esophageal cancer	2.52e-05	0.00011	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—PTGS2—esophageal cancer	2.3e-05	0.000101	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—PIK3CA—esophageal cancer	2.17e-05	9.47e-05	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—EP300—esophageal cancer	1.91e-05	8.37e-05	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.42e-05	6.19e-05	CbGpPWpGaD
